



Department
of Health &
Social Care

*From Baroness Merron
Parliamentary Under-Secretary of State for
Patient Safety, Women's Health and Mental
Health*

*39 Victoria Street
London
SW1H 0EU*

11 March 2025

Dear Colleagues

I want to thank you for your contributions to the Oral Parliamentary Question on 27 February 2025 regarding prostate cancer.

I am writing to provide additional clarity to some remarks I made during the debate. When responding to the question from Lord Grayling regarding the use of Prostate Specific Antigen (PSA) tests to detect prostate cancer, I stated, "that is why we've got the trial and that is why it will report later this year".

I meant to say that the TRANSFORM trial, looking at better methods of detecting prostate cancer, is recruiting this year. It will run for approximately a decade and will periodically report findings with the first read out expected within three years of the start of the trial. Meanwhile, the UK National Screening Committee commissioned an evidence review of screening for prostate cancer, including looking specifically at the use of PSA tests in high-risk groups. This will report later this year and will be followed with a public consultation. I apologise for any confusion caused.

I hope the above clarification proves useful. I am copying this letter to all those who contributed and the editor of Hansard. I will deposit this letter in the libraries of both Houses.

All good wishes

BARONESS MERRON